Redsense Medical AB Cash Flow Conversion Efficiency
Redsense Medical AB cash flow conversion efficiency. Based on the latest financial reports, Redsense Medical AB (REDS) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.92 Million ≈ $-206.08K USD) by net assets (Skr35.92 Million ≈ $3.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Redsense Medical AB (2020–2024)
Cash flow conversion efficiency of Redsense Medical AB from 2020 to 2024. This chart illustrates how Redsense Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View REDS share price today for real-time trading data and today's change.
Redsense Medical AB Cash Flow Conversion Ratio Explained
Redsense Medical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Redsense Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redsense Medical AB ranked by their cash flow conversion efficiency. Also see Redsense Medical AB (REDS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Max Resource Corp
V:MAX
|
-0.058x |
|
SINTX Technologies Inc
NASDAQ:SINT
|
-0.619x |
|
Shanghai Taihe Water Environmental Technology Development Co Ltd
SHG:605081
|
-0.031x |
|
ChoA Pharmaceutical Co.Ltd
KQ:034940
|
-0.016x |
|
RED LIGHT HOLLAND CORP.
F:4YX
|
-0.049x |
|
Pollen Street PLC
LSE:POLN
|
-0.005x |
|
Equinox Resources Ltd
AU:EQN
|
-0.055x |
|
BAWAT WATER TECHNOLOGIES
F:M5W
|
-3.748x |
Annual Cash Flow Conversion Efficiency for Redsense Medical AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Redsense Medical AB from 2020 to 2024. Review Redsense Medical AB free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr39.59 Million ≈ $4.26 Million |
Skr-8.23 Million ≈ $-885.57K |
-0.208x | +4.97% |
| 2023-12-31 | Skr23.09 Million ≈ $2.49 Million |
Skr-5.05 Million ≈ $-543.68K |
-0.219x | +39.29% |
| 2022-12-31 | Skr27.15 Million ≈ $2.92 Million |
Skr-9.78 Million ≈ $-1.05 Million |
-0.360x | -10.55% |
| 2021-12-31 | Skr37.49 Million ≈ $4.03 Million |
Skr-12.22 Million ≈ $-1.32 Million |
-0.326x | -238.47% |
| 2020-12-31 | Skr73.20 Million ≈ $7.88 Million |
Skr17.23 Million ≈ $1.85 Million |
0.235x | -- |
About Redsense Medical AB
Redsense Medical AB (publ) develops a monitoring system to detect sign of a blood leak using patented fiber optic technology primarily in Europe, Canada, and the United States. The company offers Redsense System, a product that is used for monitoring and alarming in the case of blood leakage during hemodialysis treatment; and Redsense venous sensor patch, a noninvasive patch that consists of an o… Read more